Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib plus gemcitabine versus gemcitabine plus placebo in elderly patients with advanced non-small cell lung cancer
2007-004521-22Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Vandetanib plus gemcitabine with Gemcitabine plus placebo (2 arms). Primary endpoint: progression-free survival. Started Jun 2008; status: completed.
02
Drugs
vandetanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-004521-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004521-22.